Finance panel reviews bill to require insurance coverage for PANDAS/PANS treatments

An insurer‑coverage bill for two pediatric neuropsychiatric conditions drew a first briefing in the Bennett Finance Committee on Jan. 27. An unnamed sponsor introduced the draft and said members should hear from clinicians and affected families before deciding next steps.

The sponsor told the committee the legislation would require major medical health insurance plans to provide coverage for the medically necessary diagnosis and treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) and Pediatric Acute‑onset Neuropsychiatric Syndrome (PANS). "What this bill would do in my understanding ... would just mandate that insurance companies cover this 1 aspect of treatment that's not currently covered," said Unidentified Speaker 4, who presented constituent accounts and denial letters the sponsor said families had received.

Why it matters: advocates and a sponsor said the conditions can be sudden and severe and that some families are paying high out‑of‑pocket costs for treatments clinicians sometimes use when other approaches do not work. Committee counsel said the draft names a set of treatments that would be covered — "antibiotics, medication therapy, and mental health services to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy," according to Jen Harvey of the Office of Legislative Council, who placed the measure and its definitions on the record.

Key details: Counsel told members the draft would add a provision in Title 8 (the health insurance chapter) to require coverage for those treatments when prescribed or ordered by a treating health‑care professional. Counsel also said Medicaid was not included in the draft because federal Medicaid provisions for children (EPSDT) already require medically necessary services for pediatric patients, and that the bill’s effective date would follow a standard phased rollout for insurance mandates (plans issued, offered, or renewed on or after the effective date would be subject to it), but not later than January 2028.

Committee concerns and next steps: Members repeatedly asked for clinical witnesses and fiscal estimates. The sponsor said advocates know of about seven children in Vermont diagnosed with these disorders and that a back‑of‑the‑envelope estimate of IVIG and related services could range from tens of thousands to roughly $70,000–$100,000 per patient in extreme cases depending on frequency of treatments. Jen Harvey and other counsel flagged that a new benefit mandate could trigger a state deferral/fiscal note process and that carriers should be asked for premium‑impact estimates.

The committee agreed to seek medical testimony and cost estimates from clinicians, the Joint Fiscal Office and affected families before making a referral decision. The sponsor said the measure will likely be sent to the Health and Welfare committee for further consideration.